No Improvement in OS or PFS from Sacituzumab Govitecan Compared with Chemotherapy In Pretreated Patients with Advanced Urothelial Cancer By Ogkologos - March 24, 2025 825 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPiCS-04 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Skin cancer death rates in men risen dramatically in the last... July 14, 2022 Beating the Heat with Beets July 31, 2020 Single Mom Has To Beg For Rides To Doctor For Son... March 14, 2019 Updated Nutrition Facts Label Reflects Science on Diet and Health, including... May 19, 2020 Load more HOT NEWS Metastatic Colorectal Cancer May Spread Early in the Disease, Study Finds FDA Approves Durvalumab for Locally Advanced or Metastatic Biliary Tract Cancer Artificial Intelligence Brings Pancreatic Cancer Screening One Step Closer to Reality... High-Deductible Health Plans Linked to Delayed Diagnosis and Treatment of Breast...
